NASDAQ: FOLD

Amicus Therapeutics, Inc.

Healthcare · Biotechnology

Market Cap

$4.55B

52w High

$14.50

52w Low

$5.51

P/E

-163.73

Volume

0.00

Outstanding Shares

314.00M

Performance

Monthly returns

Not enough data to analyse price vs. fundamentals for this ticker.

Company profile

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions.

CEOBradley L. Campbell

SectorHealthcare

IndustryBiotechnology

Employees499

IPO dateMay 31, 2007

https://amicusrx.com

Valuation

Forward P/E—

EV/EBITDA86.61

Enterprise value$4.66B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth23.72%

Gross margin87.91%▼2.95%vs FY2024

Operating margin5.17%▲15.50%vs FY2024

ROE-9.89%▲65.81%vs FY2024

Analyst consensus

RatingBuy

Target price$14.86▲2.55%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

May 7, 2026

Q2 FY26 · EPS est $0.05 · Revenue est $163.71M

View